Skip to main content
APUS logo

APUS · Apimeds Pharmaceuticals US, Inc. · Executive Compensation

Track APUS — free
$1.85 +0.18 (+10.48%)
Market Cap
$2.47M
Shares
1.51M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Sungjoon Chae Appointed 2026-09-11
Sungjoon Chae Appointed 2026-05-05
Erick Frim Terminated 2026-03-25
Youngjik Cho Appointed 2026-03-25
Junyoung Yu Appointed 2026-03-25
Youngjik Cho Appointed 2026-03-25
Vin Menon Terminated 2026-03-25
Junyoung Yu Appointed 2026-03-25
Minguk Ji Appointed 2026-03-25
Youngjik Cho Appointed 2026-03-25
Erik Emerson Terminated 2026-01-02
Amir A. Dossal Resigned 2025-12-10
Dr. Vin Menon Resigned 2025-12-10
Erik Emerson Appointed 2025-12-02
Vin Menon Appointed 2025-12-02
Erik Emerson Resigned 2025-12-02
Vin Menon Appointed 2025-12-02
Amir Dossal Appointed 2025-12-02
Hankil Yoon Resigned 2025-12-02
Christopher Kim Resigned 2025-12-02
Erick J. Frim Appointed 2025-06-05
Key facts CIK 1894525 CUSIP 03771D201 Visit website